the aid library

LIST OPTIONS

Filter

8079

Global Technical Strategy for Malaria 2016–2030, 2021 Update

Pedro Alonso, Kevin Baird, David Brandling-Bennett et al. World Health Organization (WHO) (2022) C_WHO

This updated version, endorsed by the World Health Assembly in May 2021 through resolution WHA74.9, reflects lessons learned in the global malaria response over the last 5 years. While the milestones and targets remain the same, the approaches to tackling the disease, in some areas, have evolved to ... more

Download (443)

View PDF (486)

Rwanda: NATIONAL FOOD AND NUTRITION POLICY

Republic of Rwanda: Ministry of Local Government, Ministry of Health & Ministry of Agriculture and Animal Resources (2014) C2

This National Food and Nutrition Policy developed in 2013 builds on several achievements that have improved the status of nutrition and household food security in Rwanda during the past six years. The outlines ambitious but necessary strategies needed to solve serious and persistent problems includ... more

Download (249)

View PDF (363)

A step-by-step Guide to develop National Action Plans for Noma Prevention and Control in Priority Countries

World Health Organisation (WHO) (2020) C_WHO

Noma (cancrum oris) is a severe gangrenous disease of the mouth and face. It mostly affects children between the ages of 2 and 6 years living in extreme poverty. In addition to the known factors such as malnutrition, lack of vaccination in children and poor oral hygiene, several social and environme... more

Download (215)

View PDF (363)

Asthma management in low and middle income countries: case for change

Mortimer, K.; Reddel, H. K.; Pitrez, P. M.; et al. (2022) CC2

Asthma is the most common noncommunicable disease in children, and among the most common in adults. According to the most recent estimates from the Global Asthma Network Phase I study, around one in 10 children and adults have symptoms of asthma and one in 20 school-aged children have severe asthma ... more

Download (391)

View PDF (507)

The 2014 Myanmar Population and Housing Census: Thematic report on the Older Population

The Republic of the Union of Myanmar (2017) C1

Census Report Volume 4-L
Myanmar’s 2014 Census enumerated 4.5 million people aged 60 and over and by 2050 Myanmar is projected to have 13 million people in this age group.
Myanmar’s population has aged between 1973 and 2014; while the total population increased at an annual rate of 1.... more

Download (371)

View PDF (488)

“Without Education They Lose Their Future” Denial of Education to Child Asylum Seekers on the Greek Islands

Human Rights Watch (2018) C1

This report found that fewer than 15 percent of more than 3,000 school-age asylum-seeking children on the islands were enrolled in public school at the end of the 2017-2018 school year, and that in government-run camps on the islands, only about 100 children, all preschoolers, had access to formal e... more

Download (316)

View PDF (378)

MAKING IT HAPPEN: Examples of good practice in SPECIAL NEEDS EDUCATION & COMMUNITY-BASED PROGRAMMES

United Nations Educational, Scientific and Cultural Organization (UNESCO) (1993)

This monograph presents 12 reports of successful programs serving children with special needs in various nations. The program locations and the program report titles and authors are as follows: (1) Austria: "Integration Models for Elementary and Secondary Schools in Austria" (Volker Rutte)... more

Download (514)

View PDF (532)

Global breast cancer initiative implementation framework: assessing, strengthening and scaling up of services for the early detection and management of breast cancer: executive summary

World Health Organization WHO (2023) C_WHO

Breast cancer is the most common cancer worldwide and the leading cause of cancer deaths among women, disproportionately affecting low- and middle-income countries. The Global Breast Cancer Initiative strives to reduce breast cancer mortality by 2.5 percent per year, which over a 20-year period can ... more

Download (302)

View PDF (254)

Sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy

World Health Organization WHO (2022) C_WHO

WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi... more

External Link

Current challenges for confronting the public health problem of snakebite envenoming in Central America

Gutiéerrez, J. (2014) CC

Snakebite envenoming is a serious public health problem in Central America, where approximately 5,500 cases occur every year. Panama has the highest incidence and El Salvador the lowest. The majority, and most severe, cases are inflicted by the pit viper Bothrops asper (family Viperidae), locally kn... more

Download (410)

View PDF (517)

The 2014 Myanmar Population and Housing Census: Thematic report on Fertility and Nuptiality

The Republic of the Union of Myanmar (2016) C1

Census Report Volume 4-A
This thematic report presents findings on fertility and nuptiality in Myanmar. The analysis hows that the total fertility rate is 2.5 children per woman at the Union level, 1.9 children per woman for urban areas, and 2.8 children per woman for rural areas. Total fertili... more

Download (279)

View PDF (475)

A good start: advances in early childhood development

Bernard van Leer Foundation Bernard van Leer Foundation (2015)

Early childhood matters. This document looks at specific issues regarding the development of young children, in particular from a psychosocial perspective. It is published twice per year by the Bernard van Leer Foundation. The views expressed in Early Childhood Matters are those of the authors and... more

Download (240)

View PDF (477)

Ghosts in the nursery in exile—Supporting parenting in exile during the COVID‐19 pandemic

L. Schestag; Mehner-Gentner, J.; Stein, L.; et. al. (2021) CC

The early prevention project “Strong together!” supports refugee parents and their young children (0–4 years) in Berlin, Germany. It aims to mitigate the transmission of trauma to the generation born in exile. For refugee families who have only recently arrived in Germany, the COVID‐19 pande... more

Download (238)

View PDF (485)

Liberia Bolsters its Efforts Against Malaria: Launches RTS,S Vaccine in Rivercess County on World Malaria Day

World Health Organisation (WHO) (2024) C_WHO

Rivercess, Liberia, April 25, 2024 - Liberia marks a monumental milestone in its battle against malaria as it launches the highly anticipated RTS,S malaria vaccine today, coinciding with World Malaria Day, commemorated under the theme: Health Equity, Gender, and Human Rights: Accelerating the Figh... more

Download (21)

View PDF (19)

Malaria Progress Report 2024

African Union, ALMA, and RMB Partnership to End Malaria (2024) CC2

According to the WHO, there were an estimated 251 million malaria cases (95% of global cases) and 579,414 malaria deaths (97% of global deaths) in African Union Member States in 2023. 76% of these deaths were children under the age of five.

Download (260)

View PDF (386)

Preventing injuries and violence: an overview

World Health Organisation (WHO) (2022) C_WHO

This brief advocacy document highlights the burden, risks and prevention of injuries and violence, which took the lives of 4.4 million people in 2019 and constitute 8% of all deaths. Among the injury-related causes of death include road traffic crashes, drowning, falls, burns, poisoning and violence... more

Download (346)

View PDF (422)

Informal consultation on end-game challenges for trachoma elimination

World Health Organization WHO (2022) C_WHO

Since 1996, trachoma has been targeted for elimination as a public health problem worldwide. The active trachoma criterion for national elimination as a public health problem is a TF1–9 < 5%, sustained for at least two years in the absence of antibiotic mass drug administration (MDA), in each form... more

Download (470)

View PDF (477)

Protecting Civilians from the Effects of Explosive Weapons - An Analysis of International Legal and Policy Standards

Brehm, M United Nations Institute for Disarmament Research (UNIDIR)ESEARCH (2012) C3

The use of explosive weapons, such as bombs, rockets, and mortar and artillery shells, in cities, towns and villages and in other populated areas has devastating humanitarian consequences. Explosive weapons act mainly through the projection of blast and fragmentation wi... more

Download (471)

View PDF (663)

WHO recommendations on adolescent sexual and reproductive health and rights

World Health Organization WHO (2018) C_WHO

This document provides an overview of sexual and reproductive health and rights issues that may be important for the human rights, health and well-being of adolescents (aged 10–19 years) and the relevant World Health Organization (WHO) guidelines on how to address them in an easilyaccessible, user... more

Download (458)

View PDF (691)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more